Cowen and Company’s Humacyte HUMA Stock Holding History

Cowen and Company’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-240,690	Closed	-$2.45M	–	649
2021 Q2	$2.45M	Buy	+240,690	New	+$2.48M	0.13%	62

Other funds holding HUMA

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

DCP

Diameter Capital Partners New York $1.07B AUM 152.29% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cowen and Company's HUMA Position: Q3 2021 in Review

Cowen and Company sold out of Humacyte (HUMA) in Q3 2021, closing a stake of 240,690 shares — an estimated $2.45M sold.

Cowen and Company first reported a position in HUMA in Q2 2021 and held it in 1 quarter. The position peaked at $2.45M in Q2 2021. 32 funds tracked by Wall St. Rank hold HUMA as of Q3 2021.

Cowen and Company reported no remaining Humacyte position as of Q3 2021 after selling out during the quarter.
Cowen and Company sold 240,690 Humacyte shares in Q3 2021, an estimated $2.45M.
Cowen and Company first reported a position in Humacyte in Q2 2021 and held it in 1 quarter.
Cowen and Company's Humacyte position peaked at $2.45M in Q2 2021.
32 funds tracked by Wall St. Rank held Humacyte as of Q3 2021.

Based on Cowen and Company's 13F filing for Q3 2021, filed 12 Nov 2021.